Scarica l'app Stockscreener
202.91
4.05%
-8.57
Dopo l'orario di chiusura:
202.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight - simplywall.st
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView
How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story - simplywall.st
Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating - Yahoo Finance
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
Ligand Pharmaceuticals is a low-risk way to bet on biopharma growth: Analyst - MSN
Octavio Espinoza sells shares under 10b5-1 plan (LGND) - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares - Investing.com India
Ligand Pharmaceuticals CFO sells $2.76 million in shares By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1m in shares By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $2,762,856.09 in Stock - MarketBeat
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals Executives Sell Shares Worth Over $3.7 Million - TradingView
Planned LGND insider sale: Ligand (LGND) CLO sells 5,000 shares - Stock Titan
Ligand Pharmaceuticals director Sabba sells $409k in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $409,851.00 in Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares By Investing.com - Investing.com Canada
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director sells $93k in stock - Investing.com India
Ligand Pharmaceuticals director sells $93k in stock By Investing.com - Investing.com Nigeria
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock - MarketBeat
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand to Participate in March Investor Conferences - The Manila Times
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Assessing Ligand Pharmaceuticals (LGND) Valuation After Strong One Year Returns And Elevated P/E Ratio - simplywall.st
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):